Drugs / recombinant human erythropoietin
recombinant human erythropoietin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01758861 | Jul 2011 → Sep 2012 | acute kidney injury | Yonsei University | Completed | Missed primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant human erythropoietin | “Recombinant human erythropoietin (EPO) is known to provide organ protection against ischemia-reperfusion injury through its pleiotropic properties.” PMID 24156702 ↗ Oct 2013 |
| Known as | EPO | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01758861 ↗ |
| Known as | rHuEPO-alpha | “EPO group received 300 IU/kg of rHuEPO-alpha via intravenous bolus administration after induction of anesthesia.” NCT01758861 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant human erythropoietin (EPO) is known to provide organ protection against ischemia-reperfusion injury through its pleiotropic properties.” PMID 24156702 ↗ Oct 2013 |
| Route | Intravenous | “The EPO group received 300 IU/kg of EPO intravenously after anesthetic induction.” PMID 24156702 ↗ Oct 2013 |